Supplemental Information from IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Table 1. Heterogeneity of Cores in Patients with Multiple Cores (N=961) Supplemental Table 2. Clinicopathological Characteristics of Cohort and Non-Cohort Patients. Supplemental Table 3. Patient/Disease Characteristics by {greater than or equal to}2+ IGF1R protein staining >0% (N=1734). Supplemental Table 4. DFS for Patients with Hormone Receptor Positive Patients Breast Tumors by IGF1R Membrane Staining (0,1+ vs 2,3+ ) N=909 (Stratified by nodal status) Supplemental Table 5. DFS for Patients with Hormone Receptor-Negative Breast Tumors by IGF1R Membrane Staining (0,1+ vs 2,3+ ) N=825 (Stratified by nodal status) Supplemental Figure 1. NCCTG N9831 Trial Incorporating Trastuzumab in Adjuvant Therapy Supplemental Figure 2. Patient Flow Diagram. Supplemental Figure 3. Disease-Free Survival by IGF1R Protein Expression in Patients with Hormone Receptor-Positive Breast Tumors. Supplemental Figure 4. Disease-Free Survival by IGF1R Protein Expression in Patients with Hormone Receptor-Negative Breast Tumors.
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361884844